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SUMMARY
The normal distribution in Northern Ireland of the genetic markers properdin
factor B (Bf) and glyoxalase I (GLO) are described. These markers are available
for comparison in disease studies, family studies and paternity studies.
INTRODUCTION
The HLA chromosomal region, or major histocompatibility complex located
on the short arm of chromosome six is a cluster of at least three gene families.
These are class I (HLA-A, HLA-B, HLA-C), class 11 (HLA-DP, HLA-DQ,
HLA-DR) and class Ill (C2 and C4 of the classical complement pathway and
properdin factor B (Bf) of the alternative complement pathway). HLA antigens
have been associated with susceptibility to certain diseases, for example
HLA-B27 and ankylosing spondylitis, HLA-DR2 and multiple sclerosis, and
HLA-DR3 and HLA-DR4 in insulin-dependent diabetes.1
The genetic marker Bf has been reported to be associated with certain diseases.
There are four alleles of Bf which can be distinguished by their electrophoretic
mobilities BfS1, BfS, BfF and BfF1. In insulin-dependent diabetes, Kirk
noted a marked association between the early onset of the disease and BfF1.2
If the patients were 10 years or less at onset of the disease the BfF1 frequency
was 19.1 %, whereas the normal BfF1 frequency of 1.3% was present in patients
acquiring the disease at 20 years or later. Dyer, in a study of 37 patients with
idiopathic membranous nephropathy, demonstrated an increase in BfF1, 21.6%
of patients being positive compared with 1.7 % of controls.3
The gene which regulates the enzyme glyoxalase I (GLO) is positioned at a
distance offive centimorgans from the MHC loci. This enzyme, which is present in
both red blood cells and leucocytes, catalyses the irreversible conversion of
reduced glutathione (GSH) and methyl glyoxal to S-lactoyl glutathione. Two
major GLO alleles exist, GLO1 and GLO2, giving rise to three phenotypes,
GLO-1, GLO-2 and GLO 2-1.
MATERIALS AND METHODS
Determination of Bf was made on 189 serum samples from blood donors who
attended the Northern Ireland Blood Transfusion Service, using the method of
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Alper in which high voltage electrophoresis is followed by immunofixation with
specific antibody to Bf.4 It was also possible to test 272 heterogeneous serum
samples taken from people who had been HLA-A, -B typed. These sera
samples were taken from kidney recipients and donors, multiple sclerosis
patients and members of staff.
Thin layer gels (0.5-1.0mm thick) of 1 % agarose in barbitone/calcium lactate
buffer pH8.6 were prepared on sheets of Gelbond (124 x 258 x 2mm)
(Pharmacia, Uppsala, Sweden) supported by glass plates. The gels were
electrophoresed at 20v/cm for two hours. Following separation, anti-factor B
(Atlantic Antibodies, Westbrook, Maine, USA) was applied evenly to the gel,
which was then incubated for one hour at 37°C. Four saline washes were carried
out on the gel to remove excess antibody and unfixed protein bands before
staining with coomassie blue R for 15 minutes. The excess stain was removed
with water, and the gels were allowed to dry before reading the Bf phenotypes
directly from the gels.
A modification ofthe starch gel electrophoretic technique5 was used todetermine
glyoxalase (GLO). Red cell haemolysates, obtained from 200 citrate phosphate
dextrose normal blood samples were applied to 1% agarose gels made up in
tris-barbital buffer pH8.0. Each gel was electrophoresed for one hourat 17v/cm.
Following separation, the gel was incubated for 20 minutes at 37°C in a buffered
methyl glyoxal and GSH mixture, then overlaid with a second gel containing
dichlorophenol-indophenol (DCIP) and 3 - (4,5,dimethylthiazol-2yI)-
2,5,diphenyltetrazolium bromide (MTT). The GLO phenotypes were read
according to the position of the clear bands in the blue background after
approximately 20 minutes. The development of the background colour is based
on GSH, in the absence of GLO, being involved in the non-enzymatic reduction
of DCIP, which is then oxidised by MTT to produce a blue formazan precipitate.
Where GLO is present, the above reaction does not occur, as GSH is utilized as a
co -factor in the irreversible enzymatic conversion of methyl glyoxal to S-lactoyl
glutathione, resulting in the clear bands in the blue formazan background.
RESULTS
It was only possible to demonstrate six of the 10 possible Bf phenotypes in the
189 samples tested becauseofthe low prevalencesof F1 and S1 . Thedistribution
of these phenotypes and the Bf gene frequencies in Northern Ireland is given in
Table 1. The absence of silent alleles in the Bf system which allows homozygosity
to be attributed to BfS and BfF individuals permits direct determination of the
gene frequencies.
TABLE I
Distribution ofBfphenotypes and gene frequencies in a Northern Ireland
population (n = 189)
Phenotypes (%) Gene frequencies
SS 105 55.6
SF 65 34.4 S 0.749
SSI 5 2.6 F 0.228
SF1 3 1.6 S1 0.013
FF 10 5.3 Fl 0.011
FF1 1 0.5
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In the HLA-A, -B typed samples, all HLA-B7 (n = 76) and HLA-B8 (n = 89)
positive individuals were positive for BfS, and of the 31 individuals positive for
HLA-B35, 30 were positive for BfF. The Bf phenotype distribution in this
heterogeneous group was very similar to that in the normal population: the
phenotype SS was present in 60% of the samples and the phenotype SF in 35%
of the samples.
The distribution of the GLO phenotypes and gene frequencies is presented in
Table 11. Calculation of the gene frequency was based on there being two alleles
of GLO present at an autosomal locus. No observations contradicted this
hypothesis.5
TABLE II




GLO 2-1 92 GLO1 0.535
GLO-2 61 GLO2 0.465
DISCUSSION
The frequency of each of the four Bf alleles in a Northern Ireland population was
compared with normal populations in Manchester,3 Wales6 and north -east
England.7 No significant difference (p> 0.05) in the frequency of BfS1, BfS, BfF
or BfF1 was detected. Previous reports have shown that linkage disequilibrium
exists between some HLA -B antigens and Bf variants: established examples are
HLA-B8 and BfS, HLA-B35 and BfF,8 and B7 and BfS.9 Although in this
study it has not been possible to determine if these HLA -B antigens are on the
same haplotype as the Bf variant, these associations appear to be present in our
population.
No significant difference (p > 0.05) was demonstrated in the frequency of
GLO- 1 or GLO -2 in this Northern Ireland population when compared with a
normal Caucasoid population studied intheVilIth Histocompatibility Workshop.'0
We are now able to study the frequency of Bf and GLO, as well as the HLA
antigens, in various diseases. The determination of Bf and GLO markers will also
be of use in family studies, with reference to recombination of genes, and in
paternity studies.
We thank Miss Denise Fulton for typing the manuscript.
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